Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431052 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Dermira.
- Completed
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT02431052 is a Phase 2 study of Acne Vulgaris that has completed, run by Dermira. The registered enrollment target is 420 participants, above the 269-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (56% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT02431052, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Dermira.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel compared to vehicle in patients with acne vulgaris.
Conditions Studied
Interventions
- OTHER Vehicle
- DRUG Olumacostat Glasaretil
Study Locations (20)
Florida
- Tory Sullivan MD PA - North Miami Beach
- International Clinical Research - US, LLC - Sanford
- MOORE Clinical Research, Inc. - Tampa
- Visions Clinical Research - Wellington
California
- T. Joseph Raoof, MD, Inc. - Encino
- University Clinical Trials, Inc. - San Diego
Michigan
- Michigan Center for Skin Care Research - Clinton Township
- Henry Ford Health System - Detroit
Tennessee
- The Skin Wellness Center - Knoxville
- International Clinical Research - Tennessee LLC - Murfreesboro
Texas
- DermResearch, Inc - Austin
- J&S Studies, Inc. - College Station
Alabama
- Coastal Clinical Research, Inc. - Mobile
Kentucky
- DermResearch, PLLC - Louisville
Maryland
- Lawrence J. Green, MD, LLC - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431052
The ClinicalTrials.gov registry entry for NCT02431052 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 269-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (56% higher). The listed sponsor is Dermira, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT02431052 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT02431052 about?
NCT02431052 is a clinical study titled "A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris". The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel compared to vehicle in patients with acne vulgaris.
What is the current status of trial NCT02431052?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2015-04. Estimated completion is 2016-04.
What conditions does trial NCT02431052 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02431052?
The interventions under investigation include: Vehicle (OTHER), Olumacostat Glasaretil (DRUG).
Who is sponsoring clinical trial NCT02431052?
This trial is sponsored by Dermira, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02431052 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.